Artiva Biotherapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 24, 2025. During the meeting, stockholders elected Daniel Baker, Ph.D., as a Class I director. The appointment of KPMG LLP as the principal independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the 2024 Equity Incentive Plan, increasing the number of shares of common stock authorized for issuance by 1,214,580 shares, was also approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-089942), on June 25, 2025, and is solely responsible for the information contained therein.